This Note will address the current judicial and legislative shortcomings enabling patent thickets to develop within the pharmaceutical industry well beyond their initial twenty years and discuss potential solutions to the identified problems. It will argue for the realignment of patent incentives within the pharmaceutical field to help address the patent thicket problem in an effort to reduce transaction costs.